JW (Cayman) Therapeutics CoJWCTF 30 Gross Margin % is 60.89% as of Dec. 2025, which is 25% above its 10-year median of 48.87. GuruFocus rates JWCTF with a GF Score™ of 30/100 and a GF Value™ of $0.64 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 737 Biotechnology companies, JW (Cayman) Therapeutics Co ranks better than 50.2% on this metric.
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
JW (Cayman) Therapeutics Co had a gross margin of 60.89% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
JW (Cayman) Therapeutics Co Gross Margin % Related Terms
JW (Cayman) Therapeutics Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JWCTF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
JW (Cayman) Therapeutics Co (JWCTF) has a Gross Margin % of 60.89% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on JW (Cayman) Therapeutics Co and its competitors. This is 25% above median its historical median of 48.87. Over the past decade, JW (Cayman) Therapeutics Co's Gross Margin % has ranged from 29.37 to 61.02. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #367 out of 737 companies in the Biotechnology industry, placing it in the top 49.8%.
Is JW (Cayman) Therapeutics Co's Gross Margin % too high?
JW (Cayman) Therapeutics Co's current Gross Margin % of 60.89% is 25% above median its 10-year median of 48.87. Over the past 10 years, this metric has ranged from a low of 29.37 to a high of 61.02. The Biotechnology industry median Gross Margin % is 60.92. JW (Cayman) Therapeutics Co's value of 60.89% is 0% below this industry median. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #367 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #367 out of 737 companies for Gross Margin %. This puts JW (Cayman) Therapeutics Co in the upper half of its industry. The industry median Gross Margin % is 60.92. JW (Cayman) Therapeutics Co's value of 60.89% is 0% below this benchmark. Historically, JW (Cayman) Therapeutics Co's own Gross Margin % has ranged from 29.37 to 61.02 over the past decade. While the company's 10-year median is 48.87 vs. the industry median of 60.92, JW (Cayman) Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JW (Cayman) Therapeutics Co's current Gross Margin % of 60.89% is 0% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on JW (Cayman) Therapeutics Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JW (Cayman) Therapeutics Co's current Gross Margin % is 60.89%, which is 25% above median its own 10-year median of 48.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.64, compared to a current price of $0.24 — trading 62.9% below its estimated fair value. The current Gross Margin % is 60.89%, which is 25% above median its 10-year median of 48.87 and 0% below the Biotechnology industry median of 60.92. JW (Cayman) Therapeutics Co's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Gross Margin % is 60.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.24 is trading 62.9% below its estimated GF Value™ of $0.64.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
Gross Margin %: 60.89% (25% above median its 10-year median of 48.87)
GF Value™: $0.64 vs. price of $0.24 (62.9% below fair value)
Industry Position: 0% below the Biotechnology median (#367 of 737)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
30GF Score
Get the complete analysis for JWCTF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
